BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
127.49
-3.02 (-2.31%)
As of 12:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close130.51
Open130.23
Bid125.65 x 1400
Ask125.92 x 900
Day's range125.28 - 130.30
52-week range120.02 - 236.17
Volume231,107
Avg. volume669,978
Market cap6.905B
Beta (3Y Monthly)2.25
PE ratio (TTM)N/A
EPS (TTM)-9.51
Earnings date30 Oct 2018 - 5 Nov 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est207.81
Trade prices are not sourced from all markets
  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Fool6 days ago

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Business Wire12 days ago

    bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

    LentiGlobin was previously granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the EMA in July 2018, potentially reducing the EMA’s active review time of the MAA from 210 days to 150 days. “People living with transfusion-dependent β-thalassemia require frequent blood transfusions that are life-saving but may lead to complications, including organ failure due to iron overload,” said David Davidson, M.D., chief medical officer, bluebird bio.

  • Business Wire16 days ago

    bluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

    bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.m. ET at the Lotte New York Palace, New York City. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conferences.

  • A Look at Sage Therapeutics’ NMDA Receptor Portfolio
    Market Realist26 days ago

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.

  • Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
    Motley Foollast month

    Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory

    Cellular cancer therapies are a tough sell that could get a lot tougher.

  • Analyzing Regenxbio’s Valuation Metrics
    Market Realistlast month

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.

  • 56% of Analysts Recommend a ‘Buy’ for Editas Medicine
    Market Realistlast month

    56% of Analysts Recommend a ‘Buy’ for Editas Medicine

    In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.

  • Estimates and Recommendations for Bluebird Bio on September 6
    Market Realistlast month

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realistlast month

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • Bluebird Bio’s Valuation on September 6
    Market Realistlast month

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) is a clinical stage biotechnology company. It reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline YoY (year-over-year) compared to $16.72 million in the second quarter of 2017.

  • European Commission Approves Puma Biotechnology’s Nerlynx
    Market Realistlast month

    European Commission Approves Puma Biotechnology’s Nerlynx

    On September 4, the European Commission approved the marketing authorization of Puma Biotechnology’s Nerlynx as extended adjuvant therapy for the treatment of adults with early-stage HER2-positive (hormone receptor-2 positive) breast cancer who completed previous adjuvant trastuzumab-containing therapy less than a year ago.

  • Business Wirelast month

    bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D™ Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM

    bluebird bio has also reached general agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the clinical development program to support future marketing applications for Lenti-D in CALD. “Cerebral adrenoleukodystrophy is a genetic disease primarily affecting young boys that causes progressive damage to the brain, leading to the permanent loss of physical and cognitive function, and it is often fatal,” said David Davidson, M.D., chief medical officer, bluebird bio.

  • Software and Biotech Are Eating the World
    Zacks2 months ago

    Software and Biotech Are Eating the World

    Technology innovation is accelerating productivity, disruption and wealth creation, but what about valuations?

  • Business Wire2 months ago

    bluebird bio to Present at Investor Conferences in September

    To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences. With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built a pipeline with broad potential application in severe genetic diseases and cancer.

  • Business Wire2 months ago

    bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies

    bluebird bio, Inc. (BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets for use in bluebird bio’s established cell therapy platforms.

  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist2 months ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • How Analysts Rate Editas Medicine and Peers in August
    Market Realist2 months ago

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.

  • Motley Fool2 months ago

    Carl Icahn Fires Shots at Express Scripts

    Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.

  • Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
    Zacks2 months ago

    Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

    The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

  • Expectations from BeiGene’s Q2 2018 Earnings
    Market Realist2 months ago

    Expectations from BeiGene’s Q2 2018 Earnings

    BeiGene (BGNE) is a clinical-stage biopharmaceutical company that develops molecularly targeted and immuno-oncology drugs for cancer. BeiGene also markets the drugs Abraxane, Revlimid, and Vidaza in China under its licensing agreement with Celgene (CELG).

  • Investor's Business Daily2 months ago

    Can These Biotech Companies Catch Novartis, Gilead In CAR-T?

    Regeneron Pharmaceuticals is investing $100 million in Bluebird Bio in an immuno-oncology collaboration that could rival the likes of Novartis and Gilead Sciences.

  • Investor's Business Daily2 months ago

    Stocks Slip As Intel Downgrade Crimps Dow, Qualcomm Upgraded

    Stock futures opened in the red Monday, as chip stocks were active on analyst actions and Bluebird Bio surged on a development deal.

  • bluebird bio Prepares Its "Transition to a Commercial Company"
    Motley Fool2 months ago

    bluebird bio Prepares Its "Transition to a Commercial Company"

    The biotech expects to file a marketing application with EU regulators by the end of the year.

  • Analysts Are Mostly Positive on Neurocrine Biosciences in August
    Market Realist2 months ago

    Analysts Are Mostly Positive on Neurocrine Biosciences in August

    In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.

  • How Neurocrine Biosciences Performed in the Second Quarter
    Market Realist2 months ago

    How Neurocrine Biosciences Performed in the Second Quarter

    Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.